INCYTE CORPORATION Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
INCYTE CORPORATION (INCY) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $92.48 million as of 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-10
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $92.48M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $100.79M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $96.47M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $83.14M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $92.48M 10-K · filed 2026-02-10 |
| 2024-12-31 | $100.79M 10-K · filed 2026-02-10 |
| 2023-12-31 | $96.47M 10-K · filed 2025-02-10 |
| 2022-12-31 | $83.14M 10-K · filed 2024-02-13 |
| 2021-12-31 | $83.00M 10-K · filed 2023-02-07 |
| 2020-12-31 | $75.87M 10-K · filed 2022-02-08 |
| 2019-12-31 | $67.34M 10-K · filed 2021-02-09 |
| 2018-12-31 | $58.19M 10-K · filed 2020-02-13 |
| 2017-12-31 | $44.65M 10-K · filed 2019-02-14 |
| 2016-12-31 | $56.37M 10-K · filed 2018-02-15 |
| 2015-12-31 | $39.03M 10-K · filed 2017-02-14 |
| 2014-12-31 | $31.25M 10-K · filed 2016-02-12 |
| 2013-12-31 | $23.00M 10-K · filed 2015-02-17 |
| 2012-12-31 | $22.00M 10-K · filed 2014-02-21 |
| 2011-12-31 | $17.00M 10-K · filed 2013-02-21 |
| 2010-12-31 | $11.00M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |